1
|
Ledgerwood MM, Ojeda-Fournier H, Patterson R, Hasteh F, Andre MP, Cadmus L, Blair S. OT2-04-02: Metformin for Breast Cancer Prevention: A Pilot Study. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-ot2-04-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
There is a body of accumulating evidence connecting metformin, a biguanide derivative which reduces hepatic gluconeogensis and improves skeletal muscle insulin sensitivity, to reduced breast cancer risk. This, in addition to a well established drug safety record among diabetics and non-diabetics, has provoked an interest in further study of metformin's effects on breast cancer risk indicators. In our study, we examine the effects of metformin on breast density and proliferative cell marker Ki67, both indicators of breast cancer risk. This is a small observational pilot study to determine the feasibility of subject recruitment, data collection through fine-needle aspiration, and breast density measurement.
Trial Design: Recruitment of 10 breast surgery patients with high risk histology to: 1. Undergo peri-areolar fine needle aspiration (RPFNA) used to collect breast cells for analysis of proliferative marker Ki67. 2. Breast density assessment by a) mammography (the standard method) and b) whole-breast ultrasound (an innovative method recently developed at UCSD).
Each subject will undergo a single view mammogram, whole-breast ultrasound, and intra-operative RPFNA. No drug or therapeutic intervention will take place in this pilot study.
Eligibility: Female undergoing excisional high risk breast surgery.
Specific Aims: Aim 1. To determine the feasibility of recruiting high risk breast surgery patients to an observational study involving RPFNA, mammography, and whole-breast ultrasound.
Aim 2. a) To compare mammography and whole-breast ultrasound for measurement of breast density. b) To examine potential for detecting biomarkers of cell proliferation through RPFNA.
Statistical Method: Breast density will be determined by the ratio of fibroglandular tissue to fat measured on mammogram and WBU. Cell proliferation will be assessed by the percentage of positivity for biomarker Ki67 in breast ductal cells.
Accrual and target accrual: Five of ten breast excisional high risk breast surgery subjects have been accrued at this time.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT2-04-02.
Collapse
Affiliation(s)
| | | | | | - F Hasteh
- 1University of California, San Diego, CA
| | - MP Andre
- 1University of California, San Diego, CA
| | - L Cadmus
- 1University of California, San Diego, CA
| | - S Blair
- 1University of California, San Diego, CA
| |
Collapse
|